Denteric is developing precision immunotherapies for chronic Porphyromonas gingivalis infections.
Denteric is developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis) and related species. In so doing, its primary goal is to provide options to treat and prevent severe periodontal disease and its complications, a condition which affects approximately 1 in 10 people globally. In time, it is also possible that this approach will have relevance in additional medical conditions which are associated with P gingivalis and related species.
